### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/o7/96 \ \ Origin: Appendix 5 \ \ Amended o 1/o7/98, o 1/o9/99, o 1/o7/00, 30/09/01, 11/o3/02, o 1/o1/03, 24/10/05, o 1/o8/12, o 4/o3/13$ 

Name of ent	ity
-------------	-----

Tech Mpire Limited

ABN

-OL DELSONAI USE ONIM

88 156 377 141

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

<sup>†</sup>Class of \*securities issued or to be issued

Fully paid ordinary shares

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

33,334

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares for which quotation will be sought

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Issued at nil cost on conversion of Class C Performance Rights which have vested
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares issued on vesting of Class C Performance Rights
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	24 October 2016
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
<b>4</b>	Number of teasurities is 1	NT/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of \*securities issued N/A under an exception in rule 7.2 6g If \*securities issued under rule N/A 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. 6h If \*securities were issued under N/A rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements** 6i Calculate the entity's remaining Rule 7.1 9,871,150 issue capacity under rule 7.1 and Rule 7.1A 6,580,767 rule 7.1A – complete Annexure 1 and release to ASX Market Announcements +Issue dates 7 June 2017 7 Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. +Class Number 8 Number and +class of all 53,107,669 Fully paid +securities quoted on ASX shares (including the \*securities in 1,300,000 section 2 if applicable) which are subject to voluntary escrow until 7 July 2017)

Number of +securities issued

with security holder approval

N/A

6e

04/03/2013 Appendix 3B Page 3

ordinary

(including

shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class
12,700,000	Fully paid ordinary shares escrowed until 7 July 2017
6,500,000	Options (\$0.50, 29 June 2018).
500,000	Options (\$0.50, 29 June 2018) escrowed until 7 July 2017.
1,500,000	Options (\$0.45, 30 March 2020)
5,550,000	Class B Performance Rights escrowed until 7 July 2017. Conversion ratio into ordinary shares is 1:1.
1,950,000	Class B Performance Rights. Conversion ratio into ordinary shares is 1:1. Subject to voluntary escrow to 7 July 2017.
33,332	Class D Performance Rights, Conversion ratio into ordinary shares is 1:1.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
		L
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their	
	entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

<sup>+</sup> See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
		L
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
	±r 1.	F
33	<sup>+</sup> Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of \*securities 34 (tick one) (a) +Securities described in Part 1 (b) All other \*securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the \*securities are \*equity securities, the names of the 20 largest holders of the 35 additional \*securities, and the number and percentage of additional \*securities held by those holders

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

36

37

Appendix 3B Page 7 04/03/2013

If the \*securities are \*equity securities, a distribution schedule of the additional

\*securities setting out the number of holders in the categories

A copy of any trust deed for the additional +securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) Number of \*securities for which 38 <sup>+</sup>quotation is sought \*Class of \*securities for which 39 quotation is sought Do the \*securities rank equally in 40 all respects from the +issue date with an existing +class of quoted +securities? If the additional \*securities do not rank equally, please state: (b) the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment (d) the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another \*security, clearly identify that other \*security) Number +Class +class Number and of all 42 +securities quoted on (including the +securities in clause 38)

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 7 June 2017

(Director/Company secretary)

Print name: Clare Madelin

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	65,741,001	
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	4/7/16 – 33,334 issued as part consideration for the acquisition of Appenture d.o.o 6/6/17 – 33,334 on conversion of Class C performance rights	
"A"	65,807,699	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	9,871,150		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:			
Under an exception in rule 7.2			
Under rule 7.1A			
With security holder approval under rule 7.1 or rule 7.4			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	nil		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	9,871,150		
Note: number must be same as shown in Step 2			
Subtract "C"	nil		
Note: number must be same as shown in Step 3			
<b>Total</b> ["A" x 0.15] – "C"	9,871,150		
	[Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	65,807,669	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	6,580,767	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	nil	
"E"	nil	

04/03/2013 Appendix 3B Page 12

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	6,580,767	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	6,580,767	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.